WLWT: New Alzheimer's study at UC could be breakthrough

UC’s Alberto Espay hopes to take Alzheimer’s treatment in a new direction

A recent UC-led study that re-examines the course of Alzheimer’s treatment is being highlighted by media.

The study is a collaboration between UC and the renown Karolinska Institute in Sweden. The senior author is Alberto Espay, MD, MSc, professor of neurology and rehabilitative medicine and member of the UC Gardner Neuroscience Institute.  

Alberto Espay headshot

Alberto Espay, MD, MSc, professor of neurology and rehabilitative medicine at the UC College of Medicine and Director and Endowed Chair of the James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders.

This research contends that diminished levels of a certain brain fluid protein, called soluble amyloid peptide, contributes to Alzheimer’s dementia and not clumps, called amyloid plaques, that result when the fluid drops.  

Espays team compared the brain fluid levels of 600 Alzheimer’s individuals with clumps on their brains and found no cognitive impairment in those who had higher levels of the brain fluid protein.  

“We (researchers) have been going with the narrative,” that the clumps cause the dementia, when they do not, says Espay.  

Espay’s interviews are below:

WLWT: Channel 5:  New Alzheimer's study at UC could be breakthrough in treating the disease

WVXU: A replacement therapy may be able to rescue the brain from Alzheimer's

The research study also appears nationally and internationally:

Neuroscience Today: Prevailing Alzheimer’s theory in question with new discovery

MD India: New discovery sheds light on the pitfalls of Alzheimer’s theory

Featured image at top courtesy of Unsplash. 

Impact Lives Here

The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.